Semaglutide (administered by DV3396 pen)

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Healthy Volunteers Diabetes Mellitus, Type 2

Drug Information

Target Indication

Healthy Volunteers Diabetes Mellitus, Type 2

Clinical Trial

Last updated: 12/23/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NVO

Novo Nordisk A/S

Related Pipeline

Obesity or Overweight

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Diabetes

Obesity

Congenital Bleeding Disorder

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts